65,437 trials
Idiopathic Pulmonary Fibrosis
Primary: Absolute Change From Baseline in Percent Predicted Forced Vital Capacity (FVC) at Week 52 — -5.81; -5.24; -6.31 percent predicted FVC — p== 0.6339
Acne Vulgaris
Primary: Absolute Change in the Inflammatory Lesion Counts on the Face — 30.1; 29.8; 15.4; 16.9 Lesions
Granulomatosis With Polyangiitis (Wegener's) (GPA) · Microscopic Polyangiitis (MPA)
Primary: Composite of i) All-cause Mortality or ii) End-stage Renal Disease — 100; 109 Participants
Malaria
Primary: Infection Success of Vector Mosquitoes — 2; 3 Participants
Leukemia · Chronic Lymphocytic Leukemia · Lymphocytic Leukemia
Primary: Participants With a Response — 0; 3 Participants
Non-Small-Cell Lung Carcinoma
Primary: The Incidence and Time to Development of Common Terminology Criteria for Adverse Events, Version 3.0 (CTCAE v3.0) Grade > 3 Treatment-related Pneumonitis (TRP) — 2; 0…
Breastcancer · Breast Diseases
Primary: Number of Participants Who Have Obtained Breast Cancer Screening — 49; 29 Participants — p=.005
Smoking, Cigarette
Primary: Smoking 7-Day Point Prevalence at 12 Weeks — 2; 2; 3 Participants
Atopic Dermatitis (AD)
Primary: Per-Participant Daily Event Rate: Serious and Non-Serious Treatment Emergent Adverse Events (TEAEs) — 0.19; 0.34 events per-participant-day — p=0.075
Osteoarthritis of the Knee
Primary: Numeric Rating Scale (NRS) — 54; 31 Participants
Peripheral Arterial Occlusive Disease
Primary: Number of Participants With Primary Patency — 70; 89 Participants — p=<.0001
Intellectual Disability
Primary: Change in Difficulties in Emotional Regulation Scale (Gratz & Roemner, 2004) — 1.4; 0.8 score on a scale
Incomplete Reversal of Neuromuscular Block
Primary: Incentive Spirometry, Change From Baseline and Recovery Profile - 30 Minutes — -700; -862 mL
Glioblastoma
Primary: Objective Response Rate — 1 Participants
Arteriovenous Fistula · Hemodialysis · Dialysis Adequacy
Primary: Number of Fistula Needle Direction — 72; 92 Participants